Novel doravirine/islatravir shows similar patient outcomes to standard HIV-1 therapy

This announcement comes from IDWeek 2026, highlighting that in previously untreated adults with HIV-1, initiating therapy with the novel combination doravirine/islatravir (DOR/ISL) yields patient-reported outcomes comparable to the established regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The findings suggest similar improvements in overall health status between the two treatment options.

Originally published by gnews